Effect of angiogenesis on Solanine and VEGF antibody in chicken embryo transplantation model of human colon cancer cells
10.3969/j.issn.1671-8348.2016.03.017
- VernacularTitle:龙葵碱联合VEGF抗体对人结肠癌鸡胚移植模型血管生成的影响
- Author:
Xuefeng YANG
;
Dongxue DENG
;
Tao ZHANG
;
Weiwei NING
;
Xingbin ZHENG
;
Ming XIE
- Publication Type:Journal Article
- Keywords:
solanine;
HT-29 human colon cancer cells;
VEGF antibody;
tumor angiogenesis;
chick embryo chorioallantoic membrane
- From:
Chongqing Medicine
2016;(3):342-344,347
- CountryChina
- Language:Chinese
-
Abstract:
Objective To establish model of the chicken embryo transplantation of human colon cancer cells ,and investigate the effect of Solanine、VEGF antibody and Solanine combined with VEGF antibody on human colon cancer cells induce tumor angio‐genesis and tumor proliferation .Methods The model of the chicken embryo transplantation of human colon cancer HT‐29 cells were divided into three experimental group and control group .We added to the chick embryo chorioallantoic membrane with Sola‐nine、VEGF antibody and Solanine+ VEGF antibody mixture ,PBS was added to the control group .Then we analysed picture through the stereomicroscope and IPP 6 .0 image analysis software ,using immunohistochemistry envision method to detect of CD34 antigen and ki‐67 antigen ,and observing effect of Solanine group ,VEGF antibody group ,Solanine+ VEGF antibody group and the effect on the tumor angiogenesis and tumor proliferation .Results The tumor angiogenesis ,CD34 antigen and ki‐67 antigen of Sola‐nine+VEGF antibody group were significantly better than those of VEGF antibody group and Solanine group(P<0 .01);VEGF antibody group had statistical significant difference with Solanine group(P<0 .01);the effect of other three groups were better than that of the control group(P<0 .01) .Conclusion Solanine、VEGF antibody and Solanine combined with VEGF antibody could in‐hibit tumor angiogenesis and tumor proliferation of human colon cancer cell line HT‐29 to induce .It provides a new way for anti‐an‐giogenes .
